This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	Peroxisome proliferation- activated receptor- γ (PPARG; PPAR γ)	<p><i>In vitro</i> and mouse studies identified a series of pyrimidine-5-carboxylic acid derivatives that could help treat diabetes. SAR studies identified a lead derivative with partial PPARG agonist activity. In a mouse model of diabetes, oral delivery of the derivative lowered plasma glucose to levels comparable to those seen using Avandia rosiglitazone. Next steps include comparing the lead with other marketed drugs in animal models. GlaxoSmithKline plc markets Avandia to treat diabetes.</p> <p>At least nine other companies have PPARG agonists in development stages ranging from clinical to marketed to treat diabetes.</p> <p>SciBX 3(25); doi:10.1038/scibx.2010.771 Published online June 24, 2010</p>	Findings patented; unavailable for licensing	<p>Seto, S. <i>et al. J. Med. Chem.</i>; published online June 9, 2010; doi:10.1021/jm100443s</p> <p>Contact: Shigeki Seto, Kyorin Pharmaceutical Co. Ltd., Tochigi, Japan e-mail: shigeki.seto@mb.kyorin-pharm.co.jp</p>